A. Ruggiero, M. Megna, M.C. Annunziata, L. Abategiovanni, M. Scalvenzi, A. Tajani, G. Fabbrocini, A. Villani*  
Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy  
*Correspondence: A. Villani. E-mail: ali.vil@hotmail.it

References
1 Hay RJ, Johns NE, Williams HC et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol 2013; 134: 1527–1534.
2 Fox L, Csongradi C, Aucamp M, du Plessis J, Gerber M. Treatment Modalities for Acne. Molecules 2016;21: 1063. Published 2016 Aug 13.
3 Webster GF. Clinical review: Acne vulgaris. Br. Med J. 2002; 325: 475–479.
4 Mehtens SH, Shall L, Halpern SM. A 14-year review of a UK teledermatology service: experience of over 40 000 teleconsultations. Clin Exp Dermatol 2019; 44: 874–881.
5 Marasca C, Ruggiero A, Annunziata MC, Fabbrocini G, Megna M. Face the COVID-19 emergency: measures applied in an Italian Dermatologic Clinic [published online ahead of print, 2020 Apr 15]. J Eur Acad Dermatol Venereol. 2020;10.1111/jdv.16476.
6 Villani A, Scalvenzi M, Fabbrocini G. Teledermatology: a useful tool to fight COVID-19. Journal of Dermatological Treatment 2020; 31: 325.
7 Ford JA, Pereira A. Does teledermatology reduces secondary care referrals and is it acceptable to patients and doctors?: a service evaluation. J Eval Clin Pract. 2015; 21: 710–716.
8 Demo MLO, Marcon CEM. Comment on: ’A 14-year review of a UK teledermatology service: experience of over 40 000 teleconsultations’. Clin Exp Dermatol. 2019; 44:e242.
9 Marasca C, Ruggiero A, Fontanella G, Ferrillo M, Fabbrocini G, Villani A. Telemedicine and support groups in order to improve the adherence to treatment and health related quality of life in patients affected by inflammatory skin conditions during COVID-19 emergency [published online ahead of print, 2020 Apr 18]. Clin Exp Dermatol 2020;10.1111/ced.14245.
10 Lowitt MH, Kessler II, Kaufman CL, Hooper FJ, Siegel E. Burnett JW. Teledermatology and in-person examinations: a comparison of patient and physician perceptions and diagnostic agreement. Arch Dermatol. 1998; 134: 471–476.

DOI: 10.1111/jdv.16746

The red half-moon nail sign: a novel manifestation of coronavirus infection

Editor
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the coronavirus disease 2019 (COVID-19). The pandemic condition was declared by the WHO on 11 March 2020.

The main clinical symptoms are fever, dry cough and dyspnoea, although new symptoms are emerging, such as diarrhoea, anosmia and ageusia. The virus enters cells, likely including
those lining blood vessels, by binding to angiotensin-converting enzyme 2 (ACE2) receptors on the cell surface. Infection can also promote blood clots, heart attacks and cardiac inflammation.¹

In the literature, some dermatological manifestations have recently been reported, such as erythematous, vesiculous and urticarial rashes.²,³,⁴ However, there are no data about nail signs occurring during COVID 19.

A 60-year-old otherwise healthy woman presented with a history of fever (>38°C) and cough.

Seven days after the onset of these symptoms the patient referred dyspnoea, associated with anosmia and ageusia. Although chest X-ray examination was normal, chest CT revealed ground-glass opacity, leading to a diagnosis of bilateral interstitial pneumonia. A positive RT-PCR nasopharyngeal swab confirmed SARS-CoV-2 infection.

The patient was hospitalized and underwent oxygen therapy together with administration of several drugs, including hydroxychloroquine, lopinavir/ritonavir, ceftriaxone and heparin. Complete remission of respiratory symptoms, associated with negative nasopharyngeal swab was seen 10 days after the treatment was started.

Two weeks after symptoms onset, a distally convex half-moon-shaped red band surrounding the distal margin of the lunula appeared on all fingernails (Fig. 1). The patient denied any associated symptoms, and no other skin manifestations were observed. Her dermatological medical history was unremarkable. After one month of follow-up, the bands are still present and wider (Fig. 2).

Polydactylous erythronychia differential diagnosis includes lichen planus, Darier’s disease and the more rare primary amyloidosis and graft-versus-host disease. In all these conditions, however, erythronychia is arranged in longitudinal lines,⁵ while in our case erythronychia has an half-moon shape margining the lunula.

Transversal red bands of the nail were reported for the first time by Lindsley⁶ in four patients affected by Kawasaki disease. Unlike our case, however, in those patients the bands were localized in the distal part of the nail bed, in the so-called nail isthmus.

The pathogenesis of the half-moon-shaped transversal red bands seen in our patient after SARS-CoV-2 infection is unknown. A localized microvascular injury secondary to inflammatory immune response and a procoagulant state⁷ might play a central role. Due to the localization, we hypothesized a damage of the capillary network of the distal subungual arcade.

To the best of our knowledge, this is the first case of nail involvement. This sign is peculiar and has not been previously described even in dermatological or systemic diseases. Further studies are needed to validate our finding and to assess whether red half-moon nail could represent a pathognomonic sign of COVID19.

**Acknowledgement**

The patient in this manuscript has given written informed consent to the publication of her case details.

---

**Figure 1** Distally convex half-moon-shaped red bands surrounding the distal margin of the lunula.

**Figure 2** The half-moon-shaped red bands are still present after 1 month of follow-up on all fingernails and appear wider.
Conflict of interest
Dr. Neri, Dr. Guglielmo, Dr. Virdi, Dr. Gaspari, Dr. Starace and Dr. Piraccini have nothing to disclose.

Funding source
None.

I. Neri, A. Guglielmo,* A. Virdi, V. Gaspari, M. Starace, B.M. Piraccini
Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy
*Correspondence: A. Guglielmo. E-mail: albagoguglielmo@gmail.com

References
1 Wadman M, Couzin-Frankel J, Kaiser J, Matacic C. A rampage through the body. Science 2020; 368: 356–360.
2 Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34: e212–e213.
3 Marzano AV, Genovese G, Fabbrocini G et al. Varicella-like exanthem as a specific COVID-19-associated skin manifestation: multicenter case series of 22 patients. J Am Acad Dermatol 2020; 83: 280–285.
4 Henry D, Ackerman M, Sancelme E et al. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16472
5 Jellinek NJ. Longitudinal erythronychia: suggestions for evaluation and management. J Am Acad Dermatol 2011; 64: 167.e1–167.e11.
6 Lindsay CB. Nail-bed lines in Kawasaki disease. Am J Dis Child 1992; 146: 659–660.
7 Magro C, Mulvey JJ, Berlin D et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; 220: 1–13.

DOI: 10.1111/jdv.16747

Introductory histopathological findings may shed light on COVID-19 paediatric hyperinflammatory shock syndrome

Editor

The full clinical spectrum of SARS-CoV-2 disease (COVID-19) is not fully known. Numerous paediatric cases of hyperinflammatory shock syndrome (demonstrating features reminiscent of Kawasaki vasculitis) were recently associated with infection by COVID-19. Clinical presentation includes unrelenting fever, variable rash, conjunctivitis and abdominal pain, progressing to haemodynamic shock with severe myocardial involvement.1 Recent report from Italy reported a 30-time increase in the rate of Kawasaki-like presentation during the COVID-19 pandemic among children. In many cases, the nasopharyngeal swabs taken from these children were negative for COVID-19, and the association with COVID-19 infection is unclear.2

We hereby present an adolescent who developed distinctive scalp cutaneous lesions as part of COVID-19 hyperinflammatory shock syndrome.

A 16-year-old boy with unremarkable medical history was admitted due to 3-day history of severe abdominal pain and fever. A migratory rash composed of mildly oedematous and erythematous plaques was noted on the trunk and extremities. Echocardiography demonstrated impaired left ventricular function with dilatation. Laboratory workup revealed significant lymphopenia (up to 200 cells/µL) with mild neutrophilia, elevated creatinine levels (up to 2.65 mg/dL), elevated levels of C-reactive protein (up to 33.5 mg/dL) and D-dimer (1.61 mg/dL). Ferritin, fibrinogen and triglycerides’ levels were mildly elevated. Empiric antibiotic treatment was initiated with no improvement. Expeditiously, the patient developed multiorgan dysfunction including cardiac failure requiring mechanical ventilation and inotropic support. High-dose intravenous methylprednisolone therapy was initiated, and the patient regained normal cardiopulmonary and renal functions. Extensive investigations failed to disclose an inflammatory or infectious aetiology, including repeated RT-PCR for SARS-CoV-2 of nasopharyngeal, stool and bronchoalveolar lavage specimens. However, two serologic tests were positive for SARS-CoV-2 IgG.

Soon after cardiopulmonary stabilization was attained, two painful dusky erythematous plaques were noted over the posterior scalp (Fig. 1). A 3-millimetre punch skin biopsy revealed findings consistent with leukocytoclastic vasculitis including necrosis of the epidermis and most of the dermis with extravasation of erythrocytes and fibrin thrombi in the capillaries, as well as infiltration of neutrophils with nuclear debris in vessels’ walls (Fig. 2). Direct immunofluorescence demonstrated deposition

Figure 1 (a) Erythematous violaceous plaque over the posterior scalp, (b) hyperpigmented plaque with crusts over the posterior scalp, 5 days following the initial examination.